It is also worth mentioning the recent finding that, although miR-224 upregulation is a known negative prognostic factor in HCC, the high miR-224 phenotype in this cancer has been found associated with a better response to sorafenib, an inhibitor of several tyrosine kinase receptors, such as RET, RAF kinase, and vascular endothelial growth factor (VEGF) receptor, that is also used in MTC [34]. The gene discussed is NTRK1; the disease is hepatocellular carcinoma.